Quantitative proteomic analysis to the first commercialized liposomal paclitaxel nano-platform Lipusu revealed the molecular mechanism of the enhanced anti-tumor effect

Zhao, Minzhi; Li, Haiyun; Fan, Linyang; Ma, Yan; He, Guoqing; Lai, Wenjia; Fang, Qiaojun; Hu, Zhiyuan

doi:10.1080/21691401.2018.1489822

Cited by 9 publications

(5 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The first drug delivery systems to be launched in the market for cancer treatment were liposomes and are still most widely used due to their several positive points such as biocompatibility, biodegradability and non-immunogenicity [ 111 , 112 ]. The approved nano-based formulations for brain cancer treatment are listed in Table 6 .…”

Section: Nano-based Drug Approved For Cancer Therapy By Regulatory Au...mentioning

confidence: 99%

Addressing barriers in diffuse intrinsic pontine glioma: the transformative role of lipid nanoparticulate drug delivery

Presswala,

Aacharya,

Shah

2024

ADMET DMPK

View full text Add to dashboard Cite

Background and purpose: The brainstem tumour known as diffuse intrinsic pontine glioma (DIPG), also known as pontine glioma, infiltrative brainstem glioma is uncommon and virtually always affects children. A pontine glioma develops in the brainstem's most vulnerable region (the "pons"), which regulates a number of vital processes like respiration and blood pressure. It is particularly challenging to treat due to its location and how it invades healthy brain tissue. The hunt for a solution is continually advancing thanks to advances in modern medicine, but the correct approach is still elusive. With a particular focus on brain tumours that are incurable or recur, research is ongoing to discover fresh, practical approaches to target particular areas of the brain. Experimental approach: To successfully complete this task, a thorough literature search was carried out in reputable databases like Google Scholar, PubMed, and ScienceDirect. Key results: The present article provides a comprehensive analysis of the notable advantages of lipid nanoparticles compared to alternative nanoparticle formulations. The article delves into the intricate realm of diverse lipid-based nanoparticulate delivery systems, which are used in Diffuse Intrinsic Pontine Glioma (DIPG) which thoroughly examines preclinical and clinical studies, providing a comprehensive analysis of the effectiveness and potential of lipid nanoparticles in driving therapeutic advancements for DIPG. Conclusion: There is strong clinical data to support the promising method of using lipid-based nanoparticulate drug delivery for brain cancer treatment, which shows improved outcomes.

show abstract

Section: Nano-based Drug Approved For Cancer Therapy By Regulatory Au...mentioning

confidence: 99%

Addressing barriers in diffuse intrinsic pontine glioma: the transformative role of lipid nanoparticulate drug delivery

Presswala,

Aacharya,

Shah

2024

ADMET DMPK

View full text Add to dashboard Cite

show abstract

“…Lipusu™ is a non-pegylated liposome formulation containing paclitaxel. It is approved in China (2006), and it is indicated for the treatment of non-small cell lung cancer, and ovarian and breast cancers [ 125 ]. Genexol™ (Seoyoon Cheong, Korea) and Nanoxel™ (Seoyoon Cheong, Korea) were approved by South Korean (2007) and Indian agencies.…”

Section: Approved Nanopharmaceuticals For Clinical Uses In Cancer The...mentioning

confidence: 99%

Nano-Based Approved Pharmaceuticals for Cancer Treatment: Present and Future Challenges

Rodríguez

Caruana

Fuente³

et al. 2022

Biomolecules

112

View full text Add to dashboard Cite

Cancer is one of the main causes of death worldwide. To date, and despite the advances in conventional treatment options, therapy in cancer is still far from optimal due to the non-specific systemic biodistribution of antitumor agents. The inadequate drug concentrations at the tumor site led to an increased incidence of multiple drug resistance and the appearance of many severe undesirable side effects. Nanotechnology, through the development of nanoscale-based pharmaceuticals, has emerged to provide new and innovative drugs to overcome these limitations. In this review, we provide an overview of the approved nanomedicine for cancer treatment and the rationale behind their designs and applications. We also highlight the new approaches that are currently under investigation and the perspectives and challenges for nanopharmaceuticals, focusing on the tumor microenvironment and tumor disseminate cells as the most attractive and effective strategies for cancer treatments.

show abstract

“…Another way to enhance the water solubility of compound 9 , is the use of liposomes, as in the case of Lipusu ® agent, or encapsulation into polymer micelles as, for example, in the Nanoxel ® agent [ 50 , 51 ]. A major limitation of broader clinical use of compound 9 is also the fact that despite a successful outcome after the first series of chemotherapy with this drug, most patients experience a relapse of the disease and an increase in cancer cell resistance to the drug.…”

Section: Microtubule Inhibitorsmentioning

confidence: 99%

Mitotic Poisons in Research and Medicine

et al. 2020

View full text Add to dashboard Cite

Cancer is one of the greatest challenges of the modern medicine. Although much effort has been made in the development of novel cancer therapeutics, it still remains one of the most common causes of human death in the world, mainly in low and middle-income countries. According to the World Health Organization (WHO), cancer treatment services are not available in more then 70% of low-income countries (90% of high-income countries have them available), and also approximately 70% of cancer deaths are reported in low-income countries. Various approaches on how to combat cancer diseases have since been described, targeting cell division being among them. The so-called mitotic poisons are one of the cornerstones in cancer therapies. The idea that cancer cells usually divide almost uncontrolled and far more rapidly than normal cells have led us to think about such compounds that would take advantage of this difference and target the division of such cells. Many groups of such compounds with different modes of action have been reported so far. In this review article, the main approaches on how to target cancer cell mitosis are described, involving microtubule inhibition, targeting aurora and polo-like kinases and kinesins inhibition. The main representatives of all groups of compounds are discussed and attention has also been paid to the presence and future of the clinical use of these compounds as well as their novel derivatives, reviewing the finished and ongoing clinical trials.

show abstract

Quantitative proteomic analysis to the first commercialized liposomal paclitaxel nano-platform Lipusu revealed the molecular mechanism of the enhanced anti-tumor effect

Cited by 9 publications

References 30 publications

Addressing barriers in diffuse intrinsic pontine glioma: the transformative role of lipid nanoparticulate drug delivery

Addressing barriers in diffuse intrinsic pontine glioma: the transformative role of lipid nanoparticulate drug delivery

Nano-Based Approved Pharmaceuticals for Cancer Treatment: Present and Future Challenges

Mitotic Poisons in Research and Medicine

Contact Info

Product

Resources

About